nach oben

American Journal of Clinical Dermatology

Erschienen in:

11.11.2020 | Systematic Review

Identifying the Impacts of Acne and the Use of Questionnaires to Detect These Impacts: A Systematic Literature Review

verfasst von: Hayley Smith, Alison M. Layton, Diane Thiboutot, Abbey Smith, Heather Whitehouse, Waseem Ghumra, Meenakshi Verma, Jerry Tan, Georgina Jones, Kathryn Gilliland, Megha Patel, Elaine Otchere, Anne Eady

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Acne (syn: acne vulgaris) ranks as the most common inflammatory dermatosis treated worldwide. Acne typically affects adolescents at a time when they are undergoing maximum physical and social transitions, although prevalence studies suggest it is starting earlier and lasting longer, particularly in female patients. According to global burden of disease studies, acne causes significant psychosocial impact. Hence, identifying mechanisms to accurately measure the impact of the disease is important. Adopting an approach to harmonize and standardize measurements is now recognized as an essential part of any clinical evaluation and allows for better comparison across studies and meta-analyses.

Objective

The Acne Core Outcome Research Network (ACORN) has identified relevant domains as part of a core outcome set of measures for use in clinical studies. One of these is health-related quality of life (HRQoL). The aim of this systematic review was to provide information to inform the identification of the impacts most important to people with acne.

Methods

A synthesis of available evidence on acne impacts was constructed from a systematic review of the literature, with searches conducted in the MEDLINE, EMBASE and PsychInfo databases.

Results

We identified 408 studies from 58 countries using 138 different instruments to detect the impacts of acne. Four of the five most commonly used instruments (Dermatology Life Quality Index [DLQI], Cardiff Acne Disability Index [CADI], Acne Quality of Life scale [Acne-QoL], Hospital Anxiety and Depression Scale [HADS] and Skindex-29) do not identify specific impacts but rather quantify to what extent acne affects HRQoL. Other studies identified one or more impacts using open-ended questions or tailor-made questionnaires.

Conclusion

This review serves as a rich data source for future efforts by groups such as ACORN (that include patients and health care providers) to develop a core set of outcome measurements for use in clinical trials.

Nur mit Berechtigung zugänglich

Layton AM, Eady EA, Thiboutot DM, Tan J, the Acne Core Outcomes Research Network (ACORN) Outcomes Identification Group. Identifying what to measure in acne clinical trials: first steps towards development of a core outcome set. J Investig Dermatol. 2017;137(8):1784–6.PubMed

Barnes LE, Levender MM, Fleischer AB, Feldman SR. Quality of life measures for acne patients. Dermatol Clin. 2012;30(2):293–300.PubMed

Alexis A, Daniels SR, Johnson N, Pompilus F, Burgess SM, Harper JC. Development of a new patient-reported outcome measure for facial acne: the acne symptom and impact scale (ASIS). J Drugs Dermatol. 2014;13(3):333–40.PubMed

Anderson R, Rajagopalan R. Responsiveness of the dermatology-specific quality of life (DSQL) instrument to treatment for acne vulgaris in a placebo-controlled clinical trial. Qual Life Res. 1998;7(8):723–34.PubMed

Girman CJ, Hartmaier S, Thiboutot D, et al. Evaluating health-related quality of life in patients with facial acne: development of a self-administered questionnaire for clinical trials. Qual Life Res. 1996;5(5):481–90.PubMed

Gupta MA, Johnson AM, Gupta AK. The development of an Acne Quality of Life scale: reliability, validity, and relation to subjective acne severity in mild to moderate acne vulgaris. Acta Derm Venereol. 1998;78(6):451–6.PubMed

Rapp SR, Feldman SR, Graham G, Fleischer AB, Brenes G, Dailey M. The Acne Quality of Life Index (Acne-QOLI): development and validation of a brief instrument. Am J Clin Dermatol. 2006;7(3):185–92.PubMed

US Department of Health and Human Services, US FDA. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009.

Chernyshov PV, Zouboulis CC, Tomas-Aragones L, Jemec GB, Manolache L, Tzellos T, et al. Quality of life measurement in acne. Position paper of the European Academy of Dermatology and Venereology Task Forces on quality of life and patient oriented outcomes and acne, rosacea and hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2018;32(2):194–208. https://doi.org/10.1111/jdv.14585.CrossRefPubMed

10.

Braun V, Clark V. Using thematic analysis in psychology. Qual Res Psychol. 2008;3:2:77–101.

11.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–21.PubMed

12.

Lewis-Jones M, Finlay A. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132:942–9. https://doi.org/10.1111/j.1365-2133.1995.tb16953.x.CrossRefPubMed

13.

Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.

14.

Rosenberg M. Conceiving the self. New York: Basic Books; 1979.

15.

Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–71.PubMed

16.

17.

Chren MM, Lasek RJ, Sabek AP, Sands LP. Measurement properties of Skindex-16: a brief quality of life measure for patients with skin diseases. J Cutan Med Surg. 2001;5:105–10.PubMed

18.

Nijsten TE, Sampogna F, Chren MM, Abeni DD. Testing and reducing Skindex-29 using Rasch analysis: Skindex-17. J Investig Dermatol. 2006;126:1244–50.PubMed

19.

Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133:1433–40.PubMed

20.

Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality of life measure for patients with skin disease: reliability, validity and responsiveness. J Investig Dermatol. 1996;107:707–13.PubMed

21.

Smidt AC, Lai JS, Cella D, Patel S, Mancini AJ, Chamlin SL. Development and validation of Skindex-Teen, a quality-of-life instrument for adolescents with skin disease. Arch Dermatol. 2010;146:865–9.PubMed

22.

Ware JE, Sherboume CD. The MOS36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Mad Care. 1992;30:473–83.

23.

McLeod LD, Fehnel SE, Brandman J, Symonds T. Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. Pharmacoeconomics. 2003;21:1069–79.PubMed

24.

Maloney JM, Arbit DI, Flack M, McLaughlin-Miley C, Sevilla C. Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. Clin J Womens Health. 2001;1:123–31.

25.

Jung GW, Tse JE, Guiha I, Rao J. Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne. J Cutan Med Surg. 2013;17:114–22.PubMed

26.

Strauss JS, Leyden JJ, Lucky AS, et al. Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: a randomized trial comparing micronized isotretinoin with standard isotretinoin. J Am Acad Dermatol. 2001;45:196–207.PubMed

27.

Webster GF, Leyden JJ, Gross JA. Results of a phase III double-blind, randomised, parallel group non-inferiority study evaluating the safety and efficacy of isotretinoin-lidose in patients with severe, recalcitrant nodular acne. J Drugs Dermatol. 2014;13:665–70.PubMed

28.

Choi JM, Lew VK, Kimball AB. A single-blinded, randomized, controlled clinical trial evaluating the effect of face washing on acne vulgaris. Pediatr Dermatol. 2006;23:421–7.PubMed

29.

Winkler UH, Ferguson H, Mulders JA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception. 2004;69:469–76.PubMed

30.

Tan J, Frey MP, Thiboutot D, Layton A, Eady EA. Identifying the impacts of acne: a Delphi survey of patients and clinicians. J Cutan Med Surg. 2020;24(3):259–66. https://doi.org/10.1177/1203475420907088.CrossRefPubMed

31.

Magin P, Adams J, Heading G, Pond D, Smith W. Psychological sequelae of acne vulgaris: results of a qualitative study. Can Fam Physician. 2006;52(8):978–9.PubMed

32.

Kiassen A, Lipner S, O'Malley M, Longmire N, Cano S, Breitkopf T, et al. Development of a new patient-reported outcome measure to evaluate treatments for acne and acne scarring: the ACNE-Q. Br J Dermatol. 2019;181:1207–15. https://doi.org/10.1111/bjd.18005.CrossRef

33.

Schmitt J, Apfelbacker C, Spuls PI, Thomas KS, Simpson EL, Furue M, et al. The harmonizing outcome measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. J Investig Dermatol. 2015;135:24–30.PubMed

34.

Spielberger CD, Gorsuch RL, Lushene PR, Vagg PR, Jacobs GA. Manual for the state-trait anxiety inventory. San Jose: Consulting Psychologists Press, Inc.; 1983.

35.

Derogitas RL, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med. 1983;13:595–605.

36.

Skevington SM, Lotfy M, O'Connel KA, WHOQOL Group. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13:299–310.PubMed

37.

Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Clin Exp Dermatol. 1992;17:1–3.PubMed

38.

Fenigstein A, Scheier MF, Buss AH. Public and private self-consciousness: assessment and theory. J Consult Clin Psychol. 1975;43:522–7.

39.

Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–5.PubMed

40.

Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001;33(5):350–7.PubMed

41.

Goldberg DP, Gater R, Sartorius N, Ustun TB, Piccinelli M, Gureje O, et al. The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychol Med. 1997;27:191–7.

42.

Leibowitz MR. Social Phobia. Mod Probl Pharmacopsychiatry. 1987;22:141–73.

43.

Martin AR, Lookinbill DP, Botek A, Light J, Thiboutot D, Gitman CJ. Health-related quality of life among patients with facial acne: assessment of a new acne-specific questionnaire. Clin Exp Dermatol. 2001;26:380–5.PubMed

44.

Motley RJ, Finlay AY. How much disability is caused by acne? Clin Exp Dermatol. 1989;14:194–8.PubMed

45.

Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385–401.

46.

McNair DM, Heuchert JP, Shilony E. Profile of mood states: bibliography 1964–2002. Toronto: Multi-Health Systems; 2003.

47.

Layton AM, Seukeran D, Cunliffe WJ. Scarred for life? Dermatology. 1997;195(Suppl 1):15–211.PubMed

Titel: Identifying the Impacts of Acne and the Use of Questionnaires to Detect These Impacts: A Systematic Literature Review
verfasst von: Hayley Smith
Alison M. Layton
Diane Thiboutot
Abbey Smith
Heather Whitehouse
Waseem Ghumra
Meenakshi Verma
Jerry Tan
Georgina Jones
Kathryn Gilliland
Megha Patel
Elaine Otchere
Anne Eady
Publikationsdatum: 11.11.2020
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 2/2021
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-020-00564-6

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

16.04.2024 | Infektiologie | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Identifying the Impacts of Acne and the Use of Questionnaires to Detect These Impacts: A Systematic Literature Review

Abstract

Background

Objective

Methods

Results

Conclusion

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial

The Importance of Incorporating Human Factors in the Design and Implementation of Artificial Intelligence for Skin Cancer Diagnosis in the Real World

Use of Complementary and Alternative Medicines by Patients with Psoriasis: Results from a Study with 2562 Patients

Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?

Therapeutic Drug Monitoring in Patients with Suboptimal Response to Adalimumab for Hidradenitis Suppurativa: A Retrospective Case Series

Reply to: Cohen and Ross: “Laser-Induced Chrysiasis: A Unique Adverse Event Associated with Q-Switched Lasers”

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie